PHarmaceutical tech@2x
Diseases Central Nervous System

Sections

  • Clinical Trials
  • Supply Chain
  • Drug Development
  • Manufacturing
  • Diseases
    • Cardiovascular
    • Central Nervous System
    • Immunology
    • Infectious Diseases
    • Oncology
    • Respiratory

Most Read

  • Disease-cancelling drugs: Immuneering raises $62m in Series B round
  • Exscientia, Blue Oak partner to explore potential of bispecific drugs in CNS
  • Reversing disease pathology in amyloidosis: Attralus launches with $25m Series A

Most Recent

Drug Development

Disease-cancelling drugs: Immuneering raises $62m in Series B round

13 Jan 2021
Menu
  • News
  • Analysis
    • Features
    • Comment
    • Projects
  • Investment
  • Sectors
    • Clinical Trials
    • Supply Chain
    • Drug Development
    • Manufacturing
    • Diseases
      • Cardiovascular
      • Central Nervous System
      • Immunology
      • Infectious Diseases
      • Oncology
  • Deals
  • US Election
  • Disruption
  • Coronavirus
Partners
  • Accelerating Clinical Trials
  • Powder Handling
  • Simplifying Clinical Trials
Tools
  • Companies
    • Company A-Z
    • Company Categories
    • Product & Services
    • Company Releases
    • White Papers
    • Videos
  • Reports
  • Awards
  • Events
  • Magazine
The Company
  • About Us
  • Contact Us
  • Advertise With Us
  • Visit GlobalData
  • Login
  • Register
  • Login
  • Register
Diseases Central Nervous System

Sections

  • Clinical Trials
  • Supply Chain
  • Drug Development
  • Manufacturing
  • Diseases
    • Cardiovascular
    • Central Nervous System
    • Immunology
    • Infectious Diseases
    • Oncology
    • Respiratory

Most Read

  • Disease-cancelling drugs: Immuneering raises $62m in Series B round
  • Exscientia, Blue Oak partner to explore potential of bispecific drugs in CNS
  • Reversing disease pathology in amyloidosis: Attralus launches with $25m Series A

Most Recent

Drug Development

Disease-cancelling drugs: Immuneering raises $62m in Series B round

13 Jan 2021
Latest Central Nervous System
  • Disease-cancelling drugs: Immuneering raises $62m in Series B round
    1 week
  • Exscientia, Blue Oak partner to explore potential of bispecific drugs in CNS
    3 months
  • Reversing disease pathology in amyloidosis: Attralus launches with $25m Series A
    4 months
  • Protein misfolding and neurodegeneration: Yumanity and Proteostasis merger
    4 months
  • Disease-cancelling drugs: Immuneering raises $62m in Series B round
    1 week
  • Exscientia, Blue Oak partner to explore potential of bispecific drugs in CNS
    3 months
  • Reversing disease pathology in amyloidosis: Attralus launches with $25m Series A
    4 months
  • Protein misfolding and neurodegeneration: Yumanity and Proteostasis merger
    4 months
Disease-cancelling drugs: Immuneering raises $62m in Series B round
Drug Development

Disease-cancelling drugs: Immuneering raises $62m in Series B round

Massachusetts-based Immuneering Corporation has closed an oversubscribed $62m Series B round. The financing was led by Cormorant Asset Management. Surveyor…

13 Jan 2021

Top 5 Most Read

Analysis 2 days

Enter Amazon Pharmacy: the beginning of a great online pharmacy fight?

1
Sponsored 5 days

A standard approach to drug development for accessing the globe

2
Analysis 6 days

Genomics and Covid-19: UK’s real-time surveillance system to track viral mutations

3
Analysis 1 week

Disease-cancelling drugs: Immuneering raises $62m in Series B round

4
Analysis 1 week

Biopharma M&A: EY analysts optimistic for 2021 deals after a mixed 2020

5

Join Our Newsletter

Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Join Our Newsletter

Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Company A-Z

View All

Company Releases

View All

White Papers

View All

Videos

View All
logo-horizontal

Powered by Pharma Tech Logo

  • About Us
  • Editorial Approach
  • Contact Us
  • Terms & Conditions
  • Privacy Policy

© Copyright 2021 Verdict Media Limited.

  • Lost Password Back ⟶
  • Login
  • Register
Lost Password?
Registration is disabled.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more